Skip to main content
main-content

Hematologic cancers: Targeted therapy

Journal articles and book chapters

10-09-2018 | Chronic myeloid leukemia | Article

Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?

Aghel N, Delgado DH, Lipton JH. Leukemia 2018. doi:10.1038/s41375-018-0247-1.


31-05-2018 | B-cell lymphoma | Article

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Dimopoulos MA et al. N Engl J Med 2018; 378(25): 2399-2410. doi:10.1056/NEJMoa1802917

02-02-2018 | Mantle cell lymphoma | Article

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Rule S et al. Leukemia 2018; doi:10.1038/s41375-018-0023-2

31-10-2017 | Acute myeloid leukemia | Article

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia

This article summarizes the role of isocitrate dehydrogenase (IDH)-1 and IDH2 mutations in leukemogenesis, and covers recent clinical trials evaluating the effect of direct inhibition of IDH1 and IDH2.

Nassereddine S, Lap CJ, Haroun F et al. Ann Hematol 2017; 96:1983. doi:10.1007/s00277-017-3161-0

25-10-2017 | Acute leukemia | Article

(Immuno)proteasomes as therapeutic target in acute leukemia

The authors summarize the positioning of bortezomib, a first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective.

Cloos J, Roeten MS, Franke NE et al. Cancer Metastasis Rev 2017. doi:10.1007/s10555-017-9699-4

14-09-2017 | Multiple myeloma | Article

Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study

This phase III, randomized, controlled study evaluates the bortezomib-dexamethasone plus oral cyclophosphamide regimen versus bortezomib and dexamethasone in patients with primary refractory or relapsed multiple myeloma.

Kropff M et al. Ann Hematol 2017. DOI:10.1007/s00277-017-3065-z

12-09-2017 | Chronic myeloid leukemia | Article

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Based on an analysis of the randomized chronic myeloid leukemia study-IV trial, Hehlmann et al. show the high survival probabilities that can be achieved with imatinib-based monotherapy (400 mg/day).

Leukemia 2017. doi:10.1038/leu.2017.253

25-08-2017 | Leukemia | Article

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial

This long-term follow-up of this phase II trial of the oral multikinase inhibitor midostaurin demonstrates its durable activity and tolerability in advanced systemic mastocytosis patients.

Leukemia 2017. doi:10.1038/leu.2017.234

12-08-2017 | Multiple myeloma | Article

Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: Clinical and model-based analyses

This study showsweekly ixazomib 4 mg to have a favorable benefit–risk profile on days 1, 8, and 15 of 28-day cycles for the treatment of patients with multiple myeloma.

Gupta N, Yang H, Hanley MJ et al. Targ Oncol 2017. doi:10.1007/s11523-017-0524-3

03-08-2017 | Multiple myeloma | Article

Improved survival in Medicare patients with multiple myeloma: Findings from a large nationwide and population-based cohort

The authors examine in a real-world practice setting whether the proteasome inhibitor bortezomib and immunomodulatory drugs lenalidomide and thalidomide are effective in prolonging overall survival in newly diagnosed multiple myeloma.

Chen Y, Lairson DR, Chan W, Du XL. Med Oncol 2017;34:153. doi:10.1007/s12032-017-1001-7

28-07-2017 | Chronic lymphocytic leukemia | Article

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

The authors provide an overview of recent work on developing therapies targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia and highlight future avenues for development.

Arnason JE, Brown JR. Curr Oncol Rep 2017; 19: 61. doi:10.1007/s11912-017-0620-7

16-02-2017 | Multiple myeloma | Article

Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience

This articles reviews the clinical efficacy of immunomodulatory drugs, their structure-function relationship, molecular mechanisms of action, and associated second primary malignancies and thrombosis.

Holstein SA & McCarthy PL. Drugs 2017; 77: 505–520. doi:10.1007/s40265-017-0689-1

24-01-2017 | Multiple myeloma | Article

Proteasome inhibitors in cancer therapy

This review analyzes the latest advances and challenges resulting from the introduction of proteasome inhibitors into the clinical setting for patients with multiple myeloma.

Nat Rev Clin Oncol 2017. doi:10.1038/nrclinonc.2016.206

17-01-2017 | Chronic lymphocytic leukemia | Article

Venetoclax plus rituximab ‘attractive potential option’ for relapsed, refractory CLL

Venetoclax plus rituximab is active and well tolerated in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, shows a phase Ib trial.

10-01-2017 | Multiple myeloma | Article

Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity

A comprehensive overview of the latest updates in 2016 and a prospective look towards the therapeutic landscape in 2017 for patients with multiple myeloma. 

Nat Rev Clin Oncol 2017; 14: 73–74. doi:10.1038/nrclinonc.2016.221

29-12-2016 | Lymphoma | Article

The landscape of new drugs in lymphoma

In this review, Younes et al describe the most promising agents in clinical development for the treatment of lymphoma and provide expert opinion on new strategies that may streamline drug development.

Nat Rev Clin Oncol 2017; 14: 335–346. doi:10.1038/nrclinonc.2016.205

15-11-2016 | Acute lymphoblastic leukemia | Book chapter | Article

Therapeutic management of acute lymphoblastic leukemia

Spiekermann provides a detailed overview of the treatment recommendations for adult acute lymphoblastic leukemia developed by the European Working Group for ALL.

In: Handbook of Acute Leukemia. Edited by Hiddemann W. Springer International Publishing, 2016. doi:10.1007/978-3-319-26772-2_7

18-10-2016 | Bcr-Abl tyrosine kinase inhibitors | ReviewPaper | Article

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

A review of the benefits and risks of tyrosine kinase inhibitor treatment for patients with chronic myeloid leukemia and discussion of when to use these agents in different treatment settings.

Nat Rev Clin Oncol 2017;14: 141–154. doi:10.1038/nrclinonc.2016.139

14-10-2016 | Hematologic cancers | Article

T-cell lymphomas, a challenging disease: types, treatments, and future

Ma H & Abdul-Hay M. Int J Clin Oncol 2017; 22: 18–51. doi:10.1007/s10147-016-1045-2

27-09-2016 | Multiple myeloma | Article

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

An expert review of current treatment options for relapsed/refractory multiple myeloma, the mechanism of action of panobinostat, and how panobinostat fits into the current therapeutic landscape.

San-Miguel JF, Einsele H, & Moreau P. Adv Ther 2016; 33: 1896–1920. doi:10.1007/s12325-016-0413-7

Image Credits